At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ETNB 89Bio, Inc.
Not Yet Opened 12-18 16:00:00 EST
7.61
-0.37
-4.64%
盘后7.61
+0.000.00%
18:08 EST
High8.05Low7.40Vol1.54M
Open8.00D1 Closing7.98Amplitude8.15%
Mkt Cap894.80MTradable Cap605.97MTotal Shares117.58M
T/O11.99MT/O Rate1.93%Tradable Shares79.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
New Strong Sell Stocks for November 16th
Zacks  ·  12-16 18:59
New Strong Sell Stocks for November 16th
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
Insider Monkey  ·  12-05
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  11-30
89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
GlobeNewswire  ·  11-27
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
89bio announces new analyses of data from Phase 2b ENLIVEN trial
TIPRANKS  ·  11-15
89bio announces new analyses of data from Phase 2b ENLIVEN trial
89Bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the Enliven Phase 2B Trial in Mash Patients at Aasld the Liver Meeting® 2024
THOMSON REUTERS  ·  11-15
89Bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the Enliven Phase 2B Trial in Mash Patients at Aasld the Liver Meeting® 2024
BUZZ-U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Reuters  ·  11-14
BUZZ-U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
BUZZ-89bio slips after $125 mln stock deal
Reuters  ·  11-13
BUZZ-89bio slips after $125 mln stock deal
89bio Prices $125 Million Offering
MT Newswires Live  ·  11-13
89bio Prices $125 Million Offering
89bio drops 2%, prices $125M stock offering
seekingalpha  ·  11-13
89bio drops 2%, prices $125M stock offering
BRIEF-89Bio, Inc. Announces Upsized Pricing Of $125.0 Million Public Offering Of Common Stock And Pre-Funded Warrants
Reuters  ·  11-13
BRIEF-89Bio, Inc. Announces Upsized Pricing Of $125.0 Million Public Offering Of Common Stock And Pre-Funded Warrants
89Bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  11-13
89Bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
89Bio Inc - Prices Upsized Public Offering of 11.46 Mln Shares at $8.50 Each
THOMSON REUTERS  ·  11-13
89Bio Inc - Prices Upsized Public Offering of 11.46 Mln Shares at $8.50 Each
89bio announces $100M common stock offering
TIPRANKS  ·  11-13
89bio announces $100M common stock offering
89Bio Inc - Commences $100 Million Public Offering
THOMSON REUTERS  ·  11-13
89Bio Inc - Commences $100 Million Public Offering
89Bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  11-13
89Bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire  ·  11-13
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
TIPRANKS  ·  11-11
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
89bio Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Dow Jones  ·  11-11
89bio Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Stock Track | 89Bio Soars Despite Mixed Q3 Results as Investors Focus on Future Potential
Stock Track  ·  11-09
Stock Track | 89Bio Soars Despite Mixed Q3 Results as Investors Focus on Future Potential

Introduction

Company Name.
89Bio, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Issue price:
--